16:15 Moderator’s Opening Remarks
Kerry Chester, PhD, Professor, Molecular Medicine, University College London Cancer Institute
16:20 Bispecific, Soluble TCR as the Next Therapeutic Platform
( 作為新治療平台之雙特異性可溶性TCR )
Bahija Jallal, PhD, CEO and Director of the Board, Immunocore
Of the two adaptive immunity recognition motifs, only antibodies have been brought to patients. However, antibody therapeutics only recognize 10% of human proteome (surface-expressed). The other motif, T cell receptor (TCR), has potential to unlock 90% of the human proteome, but requires converting a low-affinity, specificity membrane receptor into a soluble therapeutic. IMCgp100, a soluble, TCR bispecific-targeting melanoma, is the most advanced soluble TCR therapeutic in development.
17:20 Attacking Cancer Cell Surfaceomes with Recombinant Antibodies
( 透過重組抗體攻擊癌細胞Surfaceome )
James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
The cell surface proteome (surfaceome) is the primary hub for cells to communicate with the outside world. Oncogenes are known to cause huge changes in cells and we find this translates to significant remodeling of the surfaceome. We generate recombinant antibodies to detect and then attack these cells by toxifying the antibodies or recruiting immune cells to kill. I’ll discuss the technologies for surface protein analysis, an industrialized platform for rapid antibody generation using phage display, and using these tool reagents for target validation.
TRACK KEYNOTE PRESENTATIONS
Antibodies with Affinity Switches
Stefan Dübel, PhD, Professor & Chair, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics
Agonists to the TNF Superfamily: Lessons Learned for TNFR2 for Autoimmunity
Denise L. Faustman, MD, PhD, Director, Immunology, Massachusetts General Hospital; Associate Professor, Medicine, Harvard Medical School
Developability Assessment to Enable Candidate Selection of Therapeutic Proteins
Steffen Hartmann, PhD, Head, Characterization, Formulation and Bioinformatics, Novartis Pharma AG
Bispecific Antibodies: Discovery, Development, and Next Generation
Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd.
Closing the Analytical 0.1-to-2 Micron-Size Gap: Why, When, and How?
Wim Jiskoot, PhD, Professor, BioTherapeutics, Leiden University
Development of Novel Immunocytokines for Cancer Immunotherapy
Christian Klein, PhD, Head, Oncology Programs, Head, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Zurich
Hot Topics in Continuous Chromatography for Protein Purification
Massimo Morbidelli, Professor, Chimica, Materiali e Ingegneria Chimica, Giulio Natta, Politecnico di Milano
Novel Formats for Antibody-Cytokine Fusion Proteins: Impact on Performance
Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich)
Turning Receptors Off and On with Bispecific Agents: Mechanistic Insights from Biophysics and Biochemistry
Andreas Plückthun, PhD, Professor & Director, Biochemistry, University of Zurich
Antibodies to Watch in 2020
Janice M. Reichert, PhD, Executive Director, The Antibody Society, and Editor-in-Chief, mAbs
Unique Engineering Targets for Antibody Production Cell Lines: Selection, Cloning, Glycan Modifications, and Chromatin Readers
Volker Sandig, PhD, CSO, ProBioGen AGVolker Sandig, PhD, CSO, ProBioGen AG
Explorations in Antibody Product Discovery
Janine Schuurman, PhD, Corporate Vice President Research & Innovation, Antibody Research & Technology, Genmab
Evolving Manufacturing Concepts and Approaches for Gene-Edited Off-the-Shelf Cell Therapy Product Candidates
David Sourdive, PhD, Executive Vice President, Technical Operations, Cellectis
How to Build a Diversified Portfolio of Pyrrolobenzodiazepine-Based Antibody-Drug Conjugates
Patrick van Berkel, PhD, Senior Vice President, R&D, ADC Therapeutics, Ltd.
Tag-on-Demand: Exploiting Amber Codon Suppression Technology for the Enrichment of High-Expressing Membrane Protein Cell Lines
Trevor Wilkinson, PhD, Associate Director, Antibody Discovery & Protein Engineering, AstraZeneca Biopharmaceuticals Unit
An International Collaboration: Towards the Standardisation of Gene Therapy
Yuan Zhao, PhD, Principal Scientist, Leader, Gene Therapy Section, Advanced Therapy Division, NIBSC, Medicines & Healthcare Products Regulatory Agency
* The program is subject to change without notice, due to unforeseen reason.